Until now multiple research groups have detected serum anti-MOG antibodies with aforementioned optimized cell-based assays, mostly in patients with a phenotype of acute disseminated encephalomyelitis (ADEM), brainstem/cortical encephalitis, optic neuritis, (ON) (unilateral/bilateral), transverse myelitis (TM) and longitudinally extensive transverse myelitis (LETM). This evidence concerns the gene MOG and transverse myelitis.